Month: May 2022

CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its first quarter ended March 31, 2022. The Company ended the quarter with approximately $247 million in cash and cash equivalents. Pyxis Oncology remains on target to file INDs for anti-EDB, PYX-201, and anti-Siglec-15, PYX-106, in the second half of 2022 and INDs for anti-CD123, PYX-203, and anti-KLRG1, PYX-102, in the second half of 2023. Further, as previously disclosed, the Company expects to provide an update on its anti-DLK1 ADC, PYX-202, in mid-2022. Financial UpdateAs of May 13, 2022, Pyxis Oncology had cash and cash equivalents of approximately $231 million (preliminary, unaudited),...

First quarter 2022 consolidated revenue of $29.0 million up 60% from the same year ago period. Adjusted EPS of $(0.25), 14% sequential improvement versus the prior quarter. Re-affirm Full Year Adjusted EBITDA guidance and remain on track to reach Consolidated Adjusted EBITDA profitability by fourth quarter 2022. Cash balance of $25.1 million as of March 31, 2022 with no debt. Cash Flow during the quarter included $7 million of one-time cash outflows related to two acquisitions and related working capital investments.NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) — LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the first quarter ended March 31, 2022. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today, May 13,...

Expands rare cannabinoid portfolio with the addition of CBT and CBDV Strengthens IP with publication of a patent application for novel cannabinoid analogs Advances the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseasesVANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., May 13, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced financial results for the third quarter of the fiscal year 2022 which ended March 31, 2022. “The third quarter of fiscal 2022 saw noticeable advancements across all of our programs, including commencing sales of the rare cannabinoids CBDV and CBT as raw ingredients for the health and wellness industry,” says...

TORONTO, May 13, 2022 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) today announces its financial results for the first quarter ending March 31, 2022 and provides an update on the Company’s activities at the Valentine Gold Project (the “Project”) in the central region of Newfoundland and Labrador (“NL”). First Quarter HighlightsAt March 31, 2022 the Company had cash and cash equivalents of $72.4 million, leaving it well positioned to execute on its permitting, development, and exploration activities at the Project; On March 31, 2022, the Company closed a US$185 million term loan credit facility with Sprott Private Resource Lending II (Collector-2) LP for the construction, development and working capital requirements of the Project; On March 17, 2022, the Company was notified that the Newfoundland...

TORONTO, May 13, 2022 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced its financial results for the first quarter ended March 31, 2022 and provided a corporate update. Chris Seto, CEO of Spectral Medical, commented, “We are pleased to report continued progress on our Tigris trial. Specifically, enrollment activity ramped up following our February investigator meeting along with the recent protocol amendment acceptance by the FDA allowing for the use of SOFA scoring as inclusion criteria into the study. We have now randomized...

Disposition of MPS programs to reduce operating expenses and extend projected cash runway into 2Q 2023 Focus R&D resources on EB-101 pivotal phase 3 VIITAL™ topline data expected in 3Q 2022 NEW YORK and CLEVELAND, May 13, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced financial results for the first quarter of 2022. The Company will host a conference call and webcast on Tuesday, May 17, 2022, at 8:30 a.m. ET, to discuss its financial results and business update. “During the quarter, we took significant steps to preserve our capital with the goal to fund operations over the next 12 months with existing cash resources,” said Vish Seshadri, Chief Executive Officer of Abeona. “First, we began off-loading our MPS assets to reduce cash burn. Second,...

Mullen more than doubles reservations on the Mullen FIVE in reported quarter. The Mullen FIVE features an estimated 325-mile range and 0-60 in 3.2 seconds. Starting price at $55,000.Q/Q cash and cash equivalents rose to +$65.2M, driven primarily by the issuance of Mullen’s Series C Preferred Stock at $8.84/share Notes payable, current portion fell approximately -10.8% Q/Q to $16.9M Total assets rose approximately 138.4% to slightly over +$100M, driven mainly by financing activities Stockholders’ equity rose favorably Q/Q from a deficit of -$10.5M to a surplus of +$52.6M Subsequent to the period ended March 31, 2022, Mullen Automotive Inc. entered into an agreement with Thurner Design to develop the Mullen FIVE RS, a high-performance EV sport crossover vehicle featuring close to 1,100 HP, 0-60 mph in 1.95 seconds, and a top speed...